Bill
Bill > AJR234
NJ AJR234
NJ AJR234Designates first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ.
summary
Introduced
11/30/2023
11/30/2023
In Committee
11/30/2023
11/30/2023
Crossed Over
Passed
Dead
01/08/2024
01/08/2024
Introduced Session
2022-2023 Regular Session
Bill Summary
This resolution designates the first full week of May of each year as "Tardive Dyskinesia Awareness Week" in NJ. Tardive Dyskinesia (TD) is a persistent, irreversible, and potentially disabling neurological condition characterized by uncontrollable repetitive movements of the face, torso, or other body parts. This involuntary movement disorder is caused by medications that help control dopamine, such as antipsychotics prescribed to treat people living with mental illnesses such as schizophrenia, bipolar disorder, and major depression. People with mental health conditions, such as bipolar disorder, major depression, schizophrenia, and schizoaffective disorder, or gastrointestinal disorders, including gastroparesis, nausea, and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs). It is estimated that about 1.1 million adults in New Jersey, or 16.14 percent of adults in the State, are living with a mental illness and as a result are likely to receive DRBAs as a form of treatment, which can lead to the onset of TD. It is vital that people taking DRBAs are monitored for TD through regular screenings as recommended by the American Psychiatric Association because long-term use of DRBAs can lead to the onset of TD. People living with TD face physical, social and emotional barriers due to the stigma associated with uncontrollable movements, which can further lead to worsened mental health symptoms and cause embarrassment or withdrawal from society. It is estimated that TD affects approximately 600,000 people in the U.S. and approximately 70 percent of people with TD have not been diagnosed. Although TD is treatable, many people with the disorder are unaware of the treatment options. Raising awareness about the symptoms and impact of TD will promote the importance of early screening, diagnosis and treatment.
AI Summary
This Joint Resolution designates the first full week of May each year as "Tardive Dyskinesia Awareness Week" in New Jersey to raise public understanding of Tardive Dyskinesia (TD), a serious and irreversible neurological condition causing involuntary repetitive movements, often a side effect of medications like antipsychotics used to treat mental health conditions such as schizophrenia and bipolar disorder, or gastrointestinal issues. These medications, known as dopamine receptor blocking agents (DRBAs), are commonly prescribed to a significant portion of New Jersey adults, and while necessary for treatment, can lead to TD. The resolution emphasizes the importance of regular screenings for individuals taking DRBAs, as many with TD are undiagnosed despite available treatments, and highlights the physical, social, and emotional challenges faced by those affected, aiming to promote early detection and intervention.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Introduced, Referred to Assembly Health Committee (on 11/30/2023)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.njleg.state.nj.us/bill-search/2022/AJR234 |
| BillText | https://pub.njleg.gov/Bills/2022/AJR/234_I1.HTM |
Loading...